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Abstract
Background: Altered Cl- homeostasis and GABAergic function are associated with nociceptive
input hypersensitivity. This study investigated the role of two major intracellular Cl- regulatory
proteins, Na+-K+-Cl- cotransporter 1 (NKCC1) and K+-Cl- cotransporter 2 (KCC2), in neuropathic
pain following spinal cord injury (SCI).
Results: Sprague-Dawley rats underwent a contusive SCI at T9 using the MASCIS impactor. The
rats developed hyperalgesia between days 21 and 42 post-SCI. Thermal hyperalgesia (TH) was
determined by a decrease in hindpaw thermal withdrawal latency time (WLT) between days 21 and
42 post-SCI. Rats with TH were then treated with either vehicle (saline containing 0.25% NaOH)
or NKCC1 inhibitor bumetanide (BU, 30 mg/kg, i.p.) in vehicle. TH was then re-measured at 1 h
post-injection. Administration of BU significantly increased the mean WLT in rats (p < 0.05). The
group administered with the vehicle alone showed no anti-hyperalgesic effects. Moreover, an
increase in NKCC1 protein expression occurred in the lesion epicenter of the spinal cord during
day 2–14 post-SCI and peaked on day 14 post-SCI (p < 0.05). Concurrently, a down-regulation of
KCC2 protein was detected during day 2–14 post-SCI. The rats with TH exhibited a sustained loss
of KCC2 protein during post-SCI days 21–42. No significant changes of these proteins were
detected in the rostral region of the spinal cord.
Conclusion: Taken together, expression of NKCC1 and KCC2 proteins was differentially altered
following SCI. The anti-hyperalgesic effect of NKCC1 inhibition suggests that normal or elevated
NKCC1 function and loss of KCC2 function play a role in the development and maintenance of
SCI-induced neuropathic pain.
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Background
Spinal cord injury (SCI) and subsequent neuropathic pain
can result in devastating motor and sensory deficits.
Chronic neuropathic pain frequently develops following
SCI and affects up to 70% of SCI patients clinically [1].
Effective analgesic therapy has been hampered by the lack
of knowledge about the mechanisms underlying post-SCI
neuropathic pain.
The GABAergic system plays an important role in spinal
nociceptive processing. GABA receptors are found on pre-
and post-synaptic sites of primary afferent terminals, as
well as interneurons in laminae I-IV in the spinal cord
dorsal horn [2]. GABAergic interneurons in the dorsal
horn are important for nociceptive attenuation [3,4]. Sub-
arachnoid implantation of GABA-producing neuronal
cells in rats attenuates allodynia and hyperalgesia follow-
ing excitotoxic injury [5]. Furthermore, administration of
the GABAA receptor agonist muscimol prevents long-last-
ing potentiation of hyperalgesia following peripheral
nerve injury [6]. However, the mechanism underlying the
derangement of the GABAergic system during neuropathic
pain state is unknown.
Normal GABAergic function is critically dependent on cat-
ion-chloride cotransporter activity, specifically inwardly
directed Na+-K+-Cl- cotransporter 1 (NKCC1) and out-
wardly directed K+-Cl-  cotransporter 2 (KCC2) [7-10].
Both NKCC1 and KCC2 are expressed in spinal cords and
function to regulate intracellular Cl-  concentration.
Increasing evidence suggests that changes of the trans-
porter expression play a role in inflammatory or neuro-
pathic pain [3,4,11,12]. Elevation of intracellular Cl- can
lead to GABAergic hypersensitivity by reversing both the
Cl- equilibrium potential (ECl) and the normal inhibitory
action of GABA. However, it remains unknown whether
NKCC1 and KCC2 play a role in chronic hyperalgesia fol-
lowing SCI.
In the current study, a contusive SCI at T9 was induced in
adult male rats using the MASCIS impactor. Inhibition of
NKCC1 with its potent antagonist bumetanide (BU) had
an anti-hyperalgesic effect in rats with chronic neuro-
pathic pain following SCI. Moreover, transient increase in
NKCC1 protein and down-regulation of KCC2 expression
were detected in the spinal cord following SCI. The results
imply that these Cl- transporter proteins may be a poten-
tial target for the development of analgesics following
SCI.
Results
Anti-hyperalgesic effects of bumetanide
In order to assess the role of ion transporters in SCI-medi-
ated hyperalgesia, it is important to verify that all animals
experienced a similar degree of injury and exhibited simi-
lar locomotor function recovery prior to anti-hyperalgesic
tests. Therefore, animals were randomly divided into one
of two groups. In both group 1 and group 2, BBB scores
showed classic locomotor function impairment after SCI
Anti-hyperalgesic effects of bumetanide Figure 1
Anti-hyperalgesic effects of bumetanide. A. No differ-
ence in locomotor function following SCI in vehicle control 
and drug treatment groups. Animals were randomly divided 
into one of two groups (group 1 and 2). Locomotor function 
was monitored and Basso, Beattie, and Bresnahan (BBB) 
scores recorded on post-SCI days 2–42 in these groups. BBB 
scores recovered with time, and reached 13.5–15.7 by day 
42 post-SCI. There were no significant differences in BBB 
scores between group 1 and group 2. B. Effects of Bumeta-
nide on TH. TH was measured and the mean withdrawal 
latency time (WLT) recorded. Group 1 received vehicle 
(0.25% NaOH in saline, i.p.) as controls (n = 4) and group 2 
received Bumetanide (BU 30 mg/kg, i.p., n = 8). After 1 h of 
treatment, TH was re-measured and the mean WLT 
recorded. Data are mean ± SD. * p < 0.05 vs. pre-SCI. # p < 
0.05 vs. vehicle.Molecular Pain 2008, 4:36 http://www.molecularpain.com/content/4/1/36
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(Figure 1A). BBB scores recovered with time, and reached
13.5–15.7 by day 42 post-SCI. There were no significant
differences in BBB scores between group 1 and group 2
(Figure 1A).
In the experiments to test anti-hyperalgesic effects of
bumetanide, group 1 served as the vehicle control and
group 2 was treated with bumetanide. Mean withdrawal
latency time (WLT) was 10.5 ± 1.7 s prior to SCI. In vehi-
cle-treated animals (group 1), the mean WLT on 21–42
days post-SCI was reduced to 6.9 ± 0.8 s (p < 0.05, Figure
1B), which is consistent with our previous findings with
SCI-induced TH [13]. Subsequent injection of the vehicle
alone had no effects on the level of SCI-induced TH (7.2
± 1.2 s). In contrast, following the administration of BU
(30 mg/kg, i.p, group 2), there was a significant increase
in mean WLT (from 6.5 ± 1.2 to 10.9 ± 1.1 s, p < 0.001),
demonstrating an anti-hyperalgesic effect of BU. Moreo-
ver, to evaluate for potential non-specific analgesic drug
effects, BU and vehicle controls were also administered in
rats which did not demonstrate TH. No significant
changes in mean WLT were observed in these animals (9.2
± 1.8 s in vehicle-treated vs. 11.0 ± 0.74 s in BU-treated
rats, p > 0.05). A lower dosage of BU (15 mg/kg, i.p.) gave
rise to a similar anti-hyperalgesic effect as was observed
with the higher dosage (WLT of 10.9 ± 2.8 vs. 7.2 ± 1.2 s
in vehicle-treated rats, p < 0.05, n = 4).
Expression of NKCC1 and KCC2 following SCI
We investigated changes in NKCC1 protein levels in the
epicenter of spinal cord tissue harvested at 2, 7, and 14
days post-SCI. A low level of NKCC1 protein was
expressed in the spinal cord tissue at baseline (Figure 2A).
βIII-tubulin was probed on the same blot to serve as con-
trol. Densitometric analysis of the NKCC1/βIII-tubulin
band ratio intensities is shown in Figure 2A. NKCC1 was
elevated on day 7 post-SCI and increased by ~60% on day
14 post-SCI (p < 0.05). In contrast, KCC2 protein was
decreased on 2 and 7 days post-SCI and significantly fell
by ~40% on day 14 post-SCI (p < 0.05, Figure 2B). How-
ever, no significant changes of βIII-tubulin were detected
in the same sample. This data indicate a significant
increase in the expression of NKCC1 and, conversely, a
decrease in KCC2 expression at the epicenter on day 14
post-SCI (prior to the chronic phase of post-SCI neuro-
pathic hyperalgesia).
To further establish that changes in NKCC1 and KCC2 are
specific to the lesion epicenter of the spinal cord in
response to SCI, we also examined spinal cord tissue ros-
tral to the SCI injury epicenter. As shown in Figure 3A,
NKCC1 protein level was low in sham control animals
and tended to increase on days 2–14 post-SCI, but did not
reach statistical significance. There were also no signifi-
cant changes in KCC2 protein expression in rostral spinal
cords on day 2–14 post-SCI (Figure 3B).
Changes of NKCC1 and KCC2 in hyperalgesia rats 
following SCI
We examined changes in NKCC1 and KCC2 protein levels
in the contusion epicenter of spinal cord during days 21–
42 post-SCI, when it was possible to determine the pres-
ence of chronic TH. As shown in Figure 4, a moderate
reduction of NKCC1 occurred on days 21–35 post-SCI.
Figure 2
B
A
KCC2
  β-Tubulin
NKCC1
  β-Tubulin
Epicenter
EpicenterMolecular Pain 2008, 4:36 http://www.molecularpain.com/content/4/1/36
Page 4 of 8
(page number not for citation purposes)
KCC2 proteins remained down-regulated during days 21
and 35 post-SCI. Interestingly, in rats exhibiting no TH,
both NKCC1 and KCC2 proteins remained unchanged as
compared to sham. In contrast, TH rats displayed a sus-
tained loss of KCC2 protein, with expression of KCC2
observed to be 34% and 40% of sham in lesion epicenter
tissue at days 28 and 35 post-SCI, respectively. Injured spi-
nal cord tissues develop neurodegeneration and severe
glial scar formation after post-SCI day 20 [14]. Therefore,
due to neuronal death and astrogliosis, no routine load-
ing control markers (such as β-tubulin III for neurons and
GFAP for glia) are appropriate for a quantitative immuno-
blotting analysis. In Figure 4, various changes of GFAP
were illustrated, reflecting astrogliosis. As a result of this
obstacle, no statistical analysis was performed. However,
at least in the post-SCI day 28 samples, when higher levels
of GFAP were detected in the spinal cord tissues in ani-
mals with neuropathic pain, the loss of KCC2 protein
remained, which strongly suggests that the decrease in
KCC2 expression is unlikely due to sample loading errors
(insufficient protein loading).
Discussion
NKCC1 and KCC2 in hyperalgesia
The inhibitory action of GABA is a critical component of
numerous neuronal circuits. It has been proposed that
large, myelinated Aβ-fibers could antagonize nociceptive
primary afferent inputs to the dorsal horn through inhib-
itory mechanisms mediated by interneurons. These
interneurons release GABA which activates GABAA recep-
tors on primary afferent terminals and produces primary
afferent depolarization (PAD). PAD shunts the magnitude
of incoming action potentials and decreases excitatory
amino release at the primary afferent central terminals
[3,4]. However, under inflamed conditions, PAD may be
enhanced such that it leads to excessive depolarization of
Expression of NKCC1 and KCC2 in rostral spinal cord tis- sues after SCI Figure 3
Expression of NKCC1 and KCC2 in rostral spinal 
cord tissues after SCI. A. Samples were prepared from 
spinal cord tissue rostral to the injury epicenter at 2, 7, and 
14 days after SCI. Top panel, the blot was probed with anti-
NKCC1 antibody (1:4000) and anti-βIII-tubulin antibody 
(1:5000). Lower panel, summary of densitometry data. Data 
are mean ± SD, n = 4. B. KCC2 expression post-SCI. Top 
panel, blots were probed with anti-KCC2 antibody (1:500) 
and anti-βIII-tubulin antibody. Lower panel, summary of den-
sitometry data. Data are mean ± SD, n = 6.
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Early changes in expression of NKCC1 and KCC2 proteins in  epicenter spinal cord tissues following SCI Figure 2
Early changes in expression of NKCC1 and KCC2 
proteins in epicenter spinal cord tissues following 
SCI. A. NKCC1 protein expression in epicenter spinal cord 
tissues at 2, 7, and 14 days post-SCI. Sham (S) samples were 
acquired from animals subject to laminectomies without sub-
sequent spinal cord contusion. Top panel, the blot was 
probed with anti-NKCC1 antibody (1:4000) and anti-βIII-
tubulin antibody (1:5000). Lower panel, Densitometric analy-
sis of the ratio of NKCC1/βIII-tubulin band intensity. Data 
were mean ± SD, n = 6. * p < 0.05 vs. Sham. B. Decrease in 
expression of KCC2 following SCI. Top panel, the blots were 
probed with anti-KCC2 antibody (1:500) and anti-βIII-tubulin 
monoclonal antibody (1:5000). Lower panel, summary of 
densitometry data for the ratio of KCC2/βIII-tubulin. Data 
were mean ± SD, n = 3. * p < 0.05 vs. S.Molecular Pain 2008, 4:36 http://www.molecularpain.com/content/4/1/36
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Aδ- and C-fibers above their thresholds for action poten-
tial generation.
Any injury-induced modification of this inhibitory action
has the potential to alter the processing of nociceptive
information in the spinal dorsal horn. Therefore, the gen-
eration of Cl--dependent GABAA receptor response is criti-
cally dependent on the activity of NKCC1 and KCC2.
NKCC1 knockout mice (NKCC1-/-) lack the GABAA recep-
tor-mediated anion outward flux current [11]. NKCC1-/-
mice have deficits in thermal nociceptive threshoulds and
display a decrease in Aβ-fiber-mediated touch-evoked
allodynia following capsaicin injection [11]. Moreover,
the NKCC1 antagonist bumetanide inhibits itch and flare
responses to histamine in human skin, and attenuates
phase I and II behavioral responses in the formalin model
of tissue injury-induced pain [15]. After intra-colonic cap-
saicin injection in mice, NKCC1 plasma membrane
expression and phosphorylation are increased in the dor-
sal spinal cord, although it is unknown whether it is
accompanied with KCC2 down-regulation [16]. Inhibi-
tion of NKCC1 and TRPV1 attenuates capsaicin-induced
allodynia [17]. These results suggest that NKCC1 plays a
role in the initiation of hyperalgesia. On the other hand,
intraplantar formalin stimulation triggers a significant
decrease in KCC2 protein expression without changes in
NKCC1 in the rat spinal cord [18]. Taken together, these
studies suggest that alteration of Cl-  homeostasis by
changes in NKCC1 and/or KCC2 may contribute to hyper-
algesia development.
NKCC1 and KCC2 in neuropathic pain
The current study examined the role of NKCC1 and KCC2
in chronic neuropathic pain following a contusion SCI.
Immunoblotting showed a significant transient up-regu-
lation of NKCC1 protein in the lesion epicenter of the rat
spinal cord on day 14 post-SCI. This was accompanied by
a concurrent down-regulation of KCC2 protein. Moreo-
ver, inhibition of NKCC1 with its potent antagonist BU
significantly reduced pain behavior in rats. These results
imply that altered NKCC1 and KCC2 expression may lead
to GABAergic derangement and contribute to the induc-
tion and maintenance of the chronic neuropathic pain
following SCI. BU inhibits NKCC1, but also KCC and
other anion transport processes (e.g., Cl-/HCO3-
exchange, Cl-  channels etc.) at higher concentrations.
However, the concentration of bumetanide (5 or 10 μM)
is relatively specific for NKCC1 [19].
Partial nerve injury (induced by a sciatic cuff) disrupted
anion homeostasis in lamina I neurons and shifted the
normally inhibitory synaptic currents to excitatory,
thereby increasing lamina I neuronal excitability in vitro
[20]. The nerve injury was associated with a decrease in
KCC2 mRNA and protein levels. Moreover, inhibition of
KCC2 activity in vivo reduces mechanical and thermal
nociceptive thresholds in control, and uninjured animals
[20]. In addition, in vivo axonal injury causes a reduction
of KCC2 mRNA in motor neurons and results in an
increased intracellular Cl-  concentration and, conse-
quently, GABAA receptor-mediated excitatory responses
[21]. A recent report shows that this transient down-regu-
lation of KCC2 [22] and the early pain behavior depends
on activation of TrkB receptor via BDNF in nerve injury
[12].
Post-translational modulation of KCC2 appears to be
involved in the down-regulation of KCC2 protein. Expos-
ing hippocampal neurons to H2O2  leads to a rapid
dephosphorylation of KCC2 protein and a subsequent
down-regulation of KCC2 protein [23]. A loss of tyrosine
Changes in NKCC1 and KCC2 expression in non-hyperalge- sic and hyperalgesic rats Figure 4
Changes in NKCC1 and KCC2 expression in non-
hyperalgesic and hyperalgesic rats. NKCC1 protein 
expression in the injury epicenter spinal cord tissues at 21, 
28, 35, and 42 days post-SCI. Sham (S) samples were 
acquired from animals subject to laminectomies without sub-
sequent spinal cord contusion. Top panel, the blot was 
probed with anti-NKCC1 antibody and anti-GFAP (glial fibril-
lary acidic protein) antibody. Lower panel, the blot was 
probed with anti-KCC2 antibody and anti-GFAP antibody. 
Hyperalgesic rats (labeled as pain) were identified with the 
thermal hyperalgesia withdrawal latency test as described 
above. (+): hyperalgesia; (-): without hyperalgesia. n = 2.
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phosphorylation of KCC2 and a reduction of surface-
expression of KCC2 in the plasma membrane is largely
attributable to tyrosine phosphatases [23]. In our current
study, reduction of KCC2 protein was detected in the epi-
center region of the spinal cord on day 14–42 following
SCI. It remains to be determined whether altered KCC2
phosphorylation is responsible for translocation between
the plasma membrane and intracellular compartments in
SCI. It is also unknown whether changes of KCC2 oli-
gomerization play a role in neuropathic pain following
SCI.
The significance of changes of NKCC1 and KCC2 proteins
following SCI is not clear. Chloride homeostasis through
the function of ionotropic GABA receptors has emerged as
one important mechanism in the development of imma-
ture neurons [8]. NKCC1 phosphorylation stimulates
neurite growth of injured adult sensory neurons [24].
Therefore, elevation of NKCC1 and down-regulation of
KCC2 in lesion epicenter may reflect the cellular repair
responses following SCI. However, the subsequent altera-
tion of Cl- homeostasis and GABAergic function causes
neuropathic pain.
Conclusion
In summary, we investigated the roles of two major intra-
cellular Cl- regulatory proteins, NKCC1 and KCC2, in
chronic neuropathic pain following contusive SCI in the
rat model. Contusive SCI caused a decrease in mean hind-
paw thermal WLT in rats during the 21–42 day period
post-SCI. Inhibition of NKCC1 with its potent antagonist
BU significantly reduced pain behavior in rats. Immunob-
lotting showed a significant transient up-regulation of
NKCC1 protein in epicenter of the rat spinal cord on day
14 post-SCI, which was accompanied by a concurrent
down-regulation of KCC2 protein. Sustained reduction of
KCC2 protein was prominent in epicenter of the spinal
cord in TH rats. These results imply that altered NKCC1
and KCC2 expression may contribute to the induction
and maintenance of the chronic neuropathic pain follow-
ing SCI.
Materials and methods
Contusion SCI
All animal procedures used in this study were conducted
in strict compliance with the National Institutes of Health
Guide for the Care and Use of Laboratory Animals and
approved by the University of Wisconsin Center for
Health Sciences Research Animal Care Committee.
Adult male Sprague-Dawley rats (250–300 g) were anes-
thetized with gaseous isoflurane in oxygen (5% for induc-
tion, 3% for maintenance) throughout the duration of
surgery. A T9 laminectomy was performed without dis-
rupting the dura mater. Stabilization vertebral clamps
were placed at T8 and T10 to the MASCIS Impactor (WM
Keck Center for Collaborative Neuroscience, Rutgers Uni-
versity, Piscataway, NJ; Model II) and the spinal cord
injured by releasing a 10 g rod (2.5 mm diameter) from a
height of 12.5 mm as described previously [13]. Bupi-
vacaine (Sensorcaine-MPF 0.25%, 0.20 ml) was adminis-
tered subcutaneously as a local anesthetic. Throughout
the procedure, body temperature was maintained at 37°C
with a constant temperature heating pad. The animals
were then returned to their cages after recovering from
anesthesia. Animals underwent daily manual bladder
expression until bladder control was re-established and
each animal received Cefalexin antibiotic (0.10 mL; 330
mg/mL in saline) for 7 days post-injury. Six rats were des-
ignated as sham controls and underwent T9 laminectomy
under anesthesia without the subsequent spinal cord con-
tusion.
Locomotor function
The functional neurological deficits due to the SCI were
assessed by behavioral analysis using the Basso, Beattie,
and Bresnahan (BBB) open-field locomotor test [25-27].
Animals were observed individually in an open field test-
ing area consisting of a plastic wading pool. BBB scores
were measured before injury (baseline) and on post-
injury days 2, 7, 14, 21, 28, 35, and 42 from video record-
ings of 4 minutes per animal. BBB scores ranged from 0
(no hind limb movement) to 21 (normal movement – i.e.
coordinated gait with parallel paw placement).
Thermal withdrawal latency time
Thermal hyperalgesia (TH) was assessed using the hind
paw withdrawal test to a thermal noxious stimulus [28].
TH is a sensitive and reproducible behavioral test of neu-
ropathic pain, which is typically exhibited in the animals
beginning approximately 21 days following SCI [13,29-
31]. Rats were placed inside the Plexiglas apparatus
(Plantar Test, Ugo Basile, Italy) and allowed to acclima-
tize. A noxious heat stimulus was applied to the plantar
surface of the hind paw and the withdrawal latency time
(WLT) recorded. Results of each test are expressed in sec-
onds (s) as the mean of six withdrawal latencies (three
from each hind paw). Animals were tested at different
time points in order to avoid a training effect. Specifically,
TH testing was performed prior to injury (baseline) and
on post-injury days 21, 28, 35, and 42. A decrease in WLT
of ≥ 2 sec from baseline is considered to be significant
[31]. Onset of TH between days 21–42 post-injury
occurred in nearly half of the injured animals, represent-
ing the chronic phase of post-SCI neuropathic hyperalge-
sia [13].
Drug preparation
The NKCC1 antagonist bumetanide (BU) stock was pre-
pared in 10 mg/mL of saline containing 0.25% NaOH.Molecular Pain 2008, 4:36 http://www.molecularpain.com/content/4/1/36
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Control vehicle was prepared as 0.25% NaOH in saline.
Control vehicle or BU (30 mg/kg) was randomly admin-
istered intraperitoneal (i.p.) into two groups (group 1,
group 2) of rats exhibiting neuropathic hyperalgesia on
post-SCI 21–42 days. TH was re-measured 1 h post-injec-
tion.
Spinal cord harvesting
Spinal cords were harvested as two 7–10 mm sections: the
epicenter of the contusion and rostral to the contusive
lesion. The sections were immediately submerged in liq-
uid nitrogen and stored at -80°C. Spinal cord samples
were harvested from animals prior to onset of the chronic
phase of neuropathic hyperalgesia (days 2, 7, and 14 fol-
lowing SCI) and on days 21, 28, 35, and 42 following SCI,
when neuropathic hyperalgesia was developed. The spinal
cords of sham control animals were harvested on day 2
post-surgery.
Sample preparation and western blotting
The harvested spinal cord segments were homogenized in
anti-phosphatase buffer (pH 7.4, mmol/L: 145 NaCl, 1.8
NaH2PO4, 8.6 Na2HPO4, 100 NaF, 10 Na4P2O7, 2
Na3VO4, 2 EDTA) and protease inhibitors as described
previously [32]. The homogenate was centrifuged at 7000
rpm for 15 min at 4°C. The supernatant was retained and
protein content of the supernatant was determined by the
BCA protein assay (Pierce; Rockford, Ill). Protein samples
(20  μg/lane) and pre-stained molecular mass markers
(Bio-Rad; Hercules, CA) were denatured in SDS sample
buffer. The samples were then electrophoretically sepa-
rated on 6% SDS gels, and the resolved proteins were elec-
trophoretically transferred to a PVDF membrane. The
blots were incubated in 7.5% nonfat dry milk in Tris-buff-
ered saline (TBS) overnight at 4°C, and then incubated for
1 h with a primary antibody. The blots were rinsed with
TBS and incubated with horseradish peroxidase-conju-
gated secondary IgG for 1 h. Bound antibody was visual-
ized using the enhanced chemiluminescence assay (ECL,
Amersham Corp; Piscataway, NJ). Monocolonal antibody
against NKCC1 (T4, 1:4000; Developmental Studies
Hybridoma Bank; Iowa City, IA), and anti-KCC2 polyclo-
nal antibody (1:500; Millipore, Billerica, MA) were used
for detection of NKCC1 and KCC2, respectively. Anti-βIII-
tubulin monoclonal antibody was used as a loading con-
trol (Promega; Madison, WI). Densitometric measure-
ment of each protein band was performed with Un-Scan-
It software (Silk Scientific; Orem, UT) and average pixel
intensity was recorded.
KCC2 exists in monomeric and oligomeric structures [33].
In the current study, all protein samples were electropho-
retically separated on 6% SDS gels in the presence of
sulthydryl-reducing agent β-mercaptoethanol (5%). As
reported by Blaesse et al [33], β-mercaptoethanol results
in the disassembly of the three oligomeric structures of
KCC2 oligomers. Therefore, we mainly analyzed changes
of KCC2 monomers in the current study (~130 kDa).
Statistical analysis
Comparisons between groups were made by student t-test
and Mann-Whitney rank sum test where necessary (Sigm-
aStat, Systat Software; Point Richmond, CA). A p < 0.05
was considered a statistically significant difference.
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